

### Appendix 3. Sensitivity analyses.

<b>Sensitivity analysis</b>	<b>All trials</b> (41 studies, n=16,364)	<b>Trials reporting WLST</b> (8 studies, n=932)	<b>Trials NOT reporting WLST</b> (33 studies, n=15,432)
Mortality rates in the control groups	22% (1,755/8,043)	15% (65/432)	22% (1,690/7,611)
Trials with positive result for the primary outcome	23/41 (56%) n=1,926	5/8 (63%) n=338	18/33 (55%) n=1,588
Trials evaluating drugs	24/41 (59%) n=12,588	6/8 (75%) n=386	18/33 (55%) n=12,202
Trials with industry funding*	9/30 (30%) n=1,849	3/7 (43%) n=142	6/23 (26%) n=1,707
Journal impact factor > 5	16/41 (39%) n=13,918	3/8 (38%) n=644	13/33 (39%) n=13,274
Date of publication after 2008	24/41 (59%) n=3,613	7/8 (88%) n=834	17/33 (52%) n=2,779

\* Source of funding was not reported in 11 trials.